FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966584481> ?p ?o ?g. }

• W2966584481 endingPage "1712" @default.
• W2966584481 startingPage "1705" @default.
• W2966584481 abstract "The objective of this study was to evaluate the cost-effectiveness of ¹⁸F-choline PET/multiparametric MRI (mpMRI) versus mpMRI alone for the detection of primary prostate cancer with a Gleason score of greater than or equal to 3 + 4 in men with elevated prostate-specific antigen levels. <b>Methods:</b> A Markov model of prostate cancer onset and progression was used to estimate the health and economic consequences of ¹⁸F-choline PET/mpMRI for the detection of primary prostate cancer with a Gleason score of greater than or equal to 3 + 4 in men with elevated prostate-specific antigen levels. Multiple simultaneous hybrid ¹⁸F-choline PET/mpMRI strategies were evaluated using Likert or Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) scoring; the first was biopsy for Likert 5 mpMRI lesions or Likert 3–4 lesions with ¹⁸F-choline target-to-background ratios of greater than or equal to 1.58, and the second was biopsy for PI-RADSv2 5 mpMRI lesions or PI-RADSv2 3–4 mpMRI lesions with ¹⁸F-choline target-to-background ratios of greater than or equal to 1.58. These strategies were compared with universal standard biopsy, mpMRI alone with biopsy only for PI-RADSv2 3–5 lesions, and mpMRI alone with biopsy only for Likert 4–5 lesions. For each mpMRI strategy, either no biopsy or standard biopsy could be performed after negative mpMRI results were obtained. Deaths averted, quality-adjusted life years (QALYs), cost, and incremental cost-effectiveness ratios were estimated for each strategy. <b>Results:</b> When the results of ¹⁸F-choline PET/mpMRI were negative, performing a standard biopsy was more expensive and had lower QALYs than performing no biopsy. The best screening strategy among those considered in this study performed hybrid ¹⁸F-choline PET/mpMRI with Likert scoring on men with elevated PSA, performed combined biopsy (targeted biopsy and standard 12-core biopsy) for men with positive imaging results, and no biopsy for men with negative imaging results ($22,706/QALY gained relative to mpMRI alone); this strategy reduced the number of biopsies by 35% in comparison to mpMRI alone. When the same policies were compared using PI-RADSv2 instead of Likert scoring, hybrid ¹⁸F-choline PET/mpMRI cost $46,867/QALY gained relative to mpMRI alone. In a threshold analysis, the best strategy among those considered remained cost-effective when the sensitivity and specificity of PET/mpMRI and combined biopsy (targeted biopsy and standard 12-core biopsy) were simultaneously reduced by 20 percentage points. <b>Conclusion:</b>¹⁸F-choline PET/mpMRI for the detection of primary prostate cancer with a Gleason score of greater than or equal to 3 + 4 is cost-effective and can reduce the number of unneeded biopsies in comparison to mpMRI alone." @default.
• W2966584481 created "2019-08-13" @default.
• W2966584481 creator A5033415518 @default.
• W2966584481 creator A5043415621 @default.
• W2966584481 creator A5059648298 @default.
• W2966584481 creator A5060220628 @default.
• W2966584481 creator A5061416618 @default.
• W2966584481 creator A5068922056 @default.
• W2966584481 date "2019-07-26" @default.
• W2966584481 modified "2023-10-12" @default.
• W2966584481 title "¹⁸F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis" @default.
• W2966584481 cites W1452095759 @default.
• W2966584481 cites W1579777493 @default.
• W2966584481 cites W1900955028 @default.
• W2966584481 cites W1978761040 @default.
• W2966584481 cites W1983991247 @default.
• W2966584481 cites W2021343669 @default.
• W2966584481 cites W2050056063 @default.
• W2966584481 cites W2057615180 @default.
• W2966584481 cites W2058056848 @default.
• W2966584481 cites W2073117151 @default.
• W2966584481 cites W2104870101 @default.
• W2966584481 cites W2105083289 @default.
• W2966584481 cites W2110881680 @default.
• W2966584481 cites W2116556918 @default.
• W2966584481 cites W2120154978 @default.
• W2966584481 cites W2120602125 @default.
• W2966584481 cites W2140495816 @default.
• W2966584481 cites W2145210296 @default.
• W2966584481 cites W2146373036 @default.
• W2966584481 cites W2165983722 @default.
• W2966584481 cites W2195877112 @default.
• W2966584481 cites W2309131942 @default.
• W2966584481 cites W2311343475 @default.
• W2966584481 cites W2417209333 @default.
• W2966584481 cites W2523396458 @default.
• W2966584481 cites W2577453388 @default.
• W2966584481 cites W2591104019 @default.
• W2966584481 cites W2601623526 @default.
• W2966584481 cites W2616433853 @default.
• W2966584481 cites W2736990592 @default.
• W2966584481 cites W2754366791 @default.
• W2966584481 cites W2786961204 @default.
• W2966584481 cites W2793905111 @default.
• W2966584481 cites W2966932594 @default.
• W2966584481 doi "https://doi.org/10.2967/jnumed.119.225771" @default.
• W2966584481 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6894371" @default.
• W2966584481 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31350321" @default.
• W2966584481 hasPublicationYear "2019" @default.
• W2966584481 type Work @default.
• W2966584481 sameAs 2966584481 @default.
• W2966584481 citedByCount "12" @default.
• W2966584481 countsByYear W29665844812019 @default.
• W2966584481 countsByYear W29665844812020 @default.
• W2966584481 countsByYear W29665844812021 @default.
• W2966584481 countsByYear W29665844812022 @default.
• W2966584481 countsByYear W29665844812023 @default.
• W2966584481 crossrefType "journal-article" @default.
• W2966584481 hasAuthorship W2966584481A5033415518 @default.
• W2966584481 hasAuthorship W2966584481A5043415621 @default.
• W2966584481 hasAuthorship W2966584481A5059648298 @default.
• W2966584481 hasAuthorship W2966584481A5060220628 @default.
• W2966584481 hasAuthorship W2966584481A5061416618 @default.
• W2966584481 hasAuthorship W2966584481A5068922056 @default.
• W2966584481 hasBestOaLocation W29665844811 @default.
• W2966584481 hasConcept C121608353 @default.
• W2966584481 hasConcept C126322002 @default.
• W2966584481 hasConcept C126838900 @default.
• W2966584481 hasConcept C2775934546 @default.
• W2966584481 hasConcept C2776235491 @default.
• W2966584481 hasConcept C2780192828 @default.
• W2966584481 hasConcept C2781123555 @default.
• W2966584481 hasConcept C2781217009 @default.
• W2966584481 hasConcept C2989005 @default.
• W2966584481 hasConcept C2992613538 @default.
• W2966584481 hasConcept C71924100 @default.
• W2966584481 hasConceptScore W2966584481C121608353 @default.
• W2966584481 hasConceptScore W2966584481C126322002 @default.
• W2966584481 hasConceptScore W2966584481C126838900 @default.
• W2966584481 hasConceptScore W2966584481C2775934546 @default.
• W2966584481 hasConceptScore W2966584481C2776235491 @default.
• W2966584481 hasConceptScore W2966584481C2780192828 @default.
• W2966584481 hasConceptScore W2966584481C2781123555 @default.
• W2966584481 hasConceptScore W2966584481C2781217009 @default.
• W2966584481 hasConceptScore W2966584481C2989005 @default.
• W2966584481 hasConceptScore W2966584481C2992613538 @default.
• W2966584481 hasConceptScore W2966584481C71924100 @default.
• W2966584481 hasIssue "12" @default.
• W2966584481 hasLocation W29665844811 @default.
• W2966584481 hasLocation W29665844812 @default.
• W2966584481 hasLocation W29665844813 @default.
• W2966584481 hasLocation W29665844814 @default.
• W2966584481 hasOpenAccess W2966584481 @default.
• W2966584481 hasPrimaryLocation W29665844811 @default.
• W2966584481 hasRelatedWork W1725314107 @default.
• W2966584481 hasRelatedWork W2032122689 @default.
• W2966584481 hasRelatedWork W2337604970 @default.
• W2966584481 hasRelatedWork W2360912380 @default.

• next